Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Shanghai Fosun Pharmaceutical Group    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP

(600196)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
10/10/2019 10/11/2019 10/14/2019 10/15/2019 10/16/2019 Date
25.5(c) 25.32(c) 25.52(c) 25.26(c) 25.06 Last
14 163 758 15 909 922 17 502 752 13 211 718 11 723 979 Volume
+2.04% -0.71% +0.79% -1.02% -0.79% Change
More quotes
Financials (CNY)
Sales 2019 29 516 M
EBIT 2019 2 644 M
Net income 2019 3 296 M
Debt 2019 16 402 M
Yield 2019 1,58%
Sales 2020 35 116 M
EBIT 2020 3 822 M
Net income 2020 3 721 M
Debt 2020 17 621 M
Yield 2020 1,76%
P/E ratio 2019 19,3x
P/E ratio 2020 17,1x
EV / Sales2019 2,63x
EV / Sales2020 2,24x
Capitalization 61 157 M
More Financials
Company
Shanghai Fosun Pharmaceutical Group is a pharmaceutical group organized around 5 areas of activities: - research, development and manufacturing of medicines (71% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system... 
Sector
Pharmaceuticals
Calendar
10/21 | 01:30amShareholder meeting
More about the company
Surperformance© ratings of Shanghai Fosun Pharmaceuti
Trading Rating : Investor Rating :
More Ratings
Latest news on SHANGHAI FOSUN PHARMACEUTI
10/15SHANGHAI FOSUN PHARMACEUTICAL : Announcement - on completion of the issuance of ..
PU
10/08SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in ..
PU
08/26SHANGHAI FOSUN PHARMACEUTICAL GROUP : Half-year results
CO
08/02SHANGHAI FOSUN PHARMACEUTICAL GROUP : Ex-dividend day for final dividend
FA
03/26SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma year net down 13% to RMB2.71 billio..
AQ
03/25SHANGHAI FOSUN PHARMACEUTICAL GROUP : Annual results
CO
03/20SHANGHAI FOSUN PHARMACEUTICAL (GROUP : annual earnings release
2018China's Junshi Biosciences raises $394 million after pricing IPO at bottom of..
RE
2018Shanghai Henlius up for Hong Kong IPO
AQ
2018SHANGHAI FOSUN PHARMACEUTICAL : CS cuts Fosun Pharmaceutical to HK$29
AQ
2018SHANGHAI FOSUN PHARMACEUTICAL GROUP : 3rd quarter results
CO
2018SHANGHAI FOSUN PHARMACEUTICAL (GROUP : quaterly earnings release
2018SHANGHAI FOSUN PHARMACEUTICAL GROUP : Half-year results
CO
2018SHANGHAI FOSUN PHARMACEUTICAL (GROUP : half-yearly earnings release
2018SHANGHAI FOSUN PHARMACEUTICAL GROUP : Ex-dividend day for final dividend
FA
More news
News in other languages on SHANGHAI FOSUN PHARMACEUTI
08/02SHANGHAI FOSUN PHARMACEUTICAL GROUP : Ex-dividend day for final dividend
03/20SHANGHAI FOSUN PHARMACEUTICAL (GROUP : publication des résultats annuels
03/20SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Veröffentlichung des Jahresergebnisses
2018SHANGHAI FOSUN PHARMACEUTICAL (GROUP : publication des résultats trimestriels
2018SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Veröffentlichung des Quartalsergebnisses
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTI
More recommendations
Sector news : Generic Pharmaceuticals
10:57aJohnson & Johnson Shares Rise
DJ
10:37aGLOBAL MARKETS LIVE : Roche, Bank of America, Alphabet, MGM…
10:08aALLERGAN : Form 8.3 -
DJ
08:14aACHILLION PHARMACEUTICALS : Shares Up 84% on Buyout Deal
DJ
07:52aINCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
DJ
More sector news : Generic Pharmaceuticals
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP
Duration : Period :
Shanghai Fosun Pharmaceutical Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTI
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 32,97  CNY
Last Close Price 25,06  CNY
Spread / Highest target 47,6%
Spread / Average Target 31,5%
Spread / Lowest Target -8,42%
EPS Revisions
Managers
NameTitle
Yi Fang Wu President, CEO & Executive Director
Qi Yu Chen Co-Chairman
Fang Yao Co-Chairman
Qian Ren Chairman-Supervisory Board
Xiao Hui Guan CFO, Chief Accountant Officer & Senior VP
Sector and Competitors